期刊文献+

银杏达莫注射液治疗急性脑梗塞的临床研究 被引量:6

Clinical Research on Treatment of Yinxingdamo Injection on Acute Cerebral Infarction(ACI)
下载PDF
导出
摘要 目的观察银杏达莫注射液治疗急性脑梗塞的疗效以及对血浆内皮素(ET)和一氧化氮(NO)含量的影响。方法120例急性脑梗塞患者随机分为2组,两组常规给予溶栓、神经保护治疗。治疗组(60例)用银杏达莫注射液20mL加入5%葡萄糖注射液500mL中静脉滴注,每日1次;对照组(60例)用复方丹参注射液20mL加入5%葡萄糖注射液500mL中静脉滴注,每日1次;疗程均为14d。观察两组治疗前后及组间相关指标的变化。结果治疗组总有效率为81.67%,显著高于对照组(61.67%),差异有统计学意义(P<0.01)。治疗1疗程后显著降低血浆ET水平,治疗前后分别为(146±44.79)pg·L-1、(103.16±34.55)pg·L-1;显著提高NO含量,治疗前后分别为(49.73±28.43 ̄78.43±36.65)μmol·L-1。结论银杏达莫注射液治疗能有效地改变急性脑梗塞患者血浆ET与NO的含量。疗效显著且无毒副反应,是一种治疗脑梗塞安全,有效的药物,值得临床推广使用。 Objective To observe the effects of Yinxingdamo injection on the treatment of Acute Cerebral Infarction(ACI),and investigate the effects of the Yinxingdamo injection on endotheline(ET) and nitric oxide (NO) of ACI. Methods 120 Cases with ACI were divided into 2 groups randomly. Both groups were accepted the treatment of intrarenous thrombolysis and nerves protection.The treated group(60 cases)was given 20ml of Yinxingdamo injection in 500ml of 5% Glucose Injection by Ⅳ infusion,once a day for 14 days.The control group(60 cases)was given 20ml Compound Danshen Injection in 500ml of 5% Glucose Injection by Ⅳ infusion,also once a day for 14days.The relative indexes between the two groups were observed and compared before and after treatment. Results The total effective rate of the treatment group was 81.67%, which was much higher than that of the control group(61.67%). The difference was significant.After the treatment ET decreased significantly and NO increased apparently. Conclusion Yinxingdamo injection is a safe and effective medicine on treating ACI,which was worthy to recommand its clinical use.
作者 邵安健
出处 《现代中药研究与实践》 CAS 2008年第5期56-57,46,共3页 Research and Practice on Chinese Medicines
关键词 银杏达莫注射液 脑梗塞 ET NO 临床疗效 Yinxingdamo injection ACI ET NO clinical effect
  • 相关文献

参考文献1

二级参考文献8

  • 1Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res, 1998,92:S1-6.
  • 2International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet,1997,349:1569-1581.
  • 3CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Collaborative Group, CAST(Chinese Acute Stroke Trial). Lancet, 1997, 349: 1641-1649.
  • 4Paul SF, Karyn M, Cynthia DL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacology,1996, 50:131-139.
  • 5Pierr S, Jamme I, Robert K, et al. Ginkgo biloba extract(EGb 761) protects Na,K-ATPase isoenzymes during cerebral ischemia. Cell Mol Biol,2002,48:671-679.
  • 6Barber PA, Auer RN, Buchan AM, et al. Understanding and managing ischemic stroke. Can J Physiol Pharmacol, 2001, 79:283-296.
  • 7Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol,1998,18:485-492.
  • 8沈连忠,崔艳英,王淑仙.银杏叶提取物血液流变学研究[J].中国中药杂志,1998,23(10):622-623. 被引量:80

共引文献58

同被引文献34

引证文献6

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部